ReliTrexed

In combination w/ cisplatin for chemotherapy naive patients w/ unresectable malignant pleural mesothelioma or who are otherwise not candidates for curative surgery; for 1st-line treatment of patients w/ locally advanced or metastatic non-squamous NSCLC. In combination w/ pembrolizumab & platinum chemotherapy for 1st-line treatment of patients w/ metastatic non-squamous NSCLC, w/ no EGFR or ALK genomic tumor aberrations. Monotherapy for maintenance treatment of locally advanced or metastatic non-squamous NSCLC in patients whose disease has not progressed immediately following 1st-line treatment w/ platinum-based chemotherapy. Monotherapy for 2nd-line treatment of patients w/ locally advanced or metastatic non-squamous NSCLC.

IV In combination w/ cisplatin or as monotherapy for NSCLC after prior chemotherapy 500 mg/m² infusion over 10 min on 1st day of each 21-day cycle. Initial treatment of metastatic non-squamous NSCLC in combination w/ pembrolizumab & platinum chemotherapy Patient w/ CrCl ≥45 mL/min 500 mg/m² infusion over 10 min administered after pembrolizumab & prior to carboplatin/cisplatin on day 1 of each 21-day cycle for 4 cycles.

Hypersensitivity. Concomitant yellow fever vaccine. Lactation.

Cytotoxic Chemotherapy

L01BA04 - pemetrexed ; Belongs to the class of antimetabolites, folic acid analogues. Used in the treatment of cancer.

POM